Oppenheimer Boosts Mirati Therapeutics (NASDAQ:MRTX) Price Target to $62.00

Mirati Therapeutics (NASDAQ:MRTX – Free Report) had its price objective upped by Oppenheimer from $56.00 to $62.00 in a research note published on Wednesday, MarketBeat reports. They currently have an outperform rating on the biotechnology company’s stock. Other analysts have also issued research reports about the company. Scotiabank began coverage on Mirati Therapeutics in a […]

Related Keywords

United States ,America ,Laurie Stelzer ,Jamie Christensen ,Mirati Therapeutics Company Profile ,Acadian Asset Management ,Metlife Investment Management ,Mirati Therapeutics Inc ,Advisor Group Holdings Inc ,Blackrock Inc ,Securities Exchange Commission ,Us Bancorp ,Scotiabank ,Mirati Therapeutics ,Free Report ,Therapeutics Trading Down ,Get Free Report ,Exchange Commission ,Group Holdings ,Asset Management ,Life Investment Management ,Mirati Therapeutics Daily ,Nasdaq Mrtx ,Mrtx ,Medical ,Boost Price Target ,Oppenheimer Holdings Inc ,